Currently, there are 695.94M common shares owned by the public and among those 401.31M shares have been available to trade.
The company’s stock has a 5-day price change of 4.60% and 15.21% over the past three months. ROIV shares are trading 1.07% year to date (YTD), with the 12-month market performance down to -3.97% lower. It has a 12-month low price of $8.73 and touched a high of $13.06 over the same period. ROIV has an average intraday trading volume of 6.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.79%, 1.94%, and 1.63% respectively.
Institutional ownership of Roivant Sciences Ltd (NASDAQ: ROIV) shares accounts for 65.73% of the company’s 695.94M shares outstanding.
It has a market capitalization of $7.72B and a beta (3y monthly) value of 1.15. The earnings-per-share (ttm) stands at -$0.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.43% over the week and 2.95% over the month.
Analysts forecast that Roivant Sciences Ltd (ROIV) will achieve an EPS of -0.23 for the current quarter, -0.25 for the next quarter and -1.25 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.29 while analysts give the company a high EPS estimate of -0.29. Comparatively, EPS for the current quarter was -0.18 a year ago. Earnings per share for the fiscal year are expected to decrease by -393.55%, and -8.50% over the next financial year.
Looking at the support for the ROIV, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on July 10, 2025, with the firm’s price target at $19. Wolfe Research coverage for the Roivant Sciences Ltd (ROIV) stock in a research note released on February 15, 2024 offered a Outperform rating with a price target of $17. Piper Sandler was of a view on January 05, 2024 that the stock is Overweight, while Deutsche Bank gave the stock Buy rating on December 12, 2023, issuing a price target of $14. Guggenheim on their part issued Buy rating on October 17, 2023.
